The Department of Veteran Affairs has allocated a portion of its new budget towards exploring the therapeutic potential of psychedelics in treating Post-Traumatic Stress Disorder (PTSD) among veterans. With a dedicated $20 million for clinical trials, the focus will be on MDMA and psilocybin, responding to long-standing requests from veteran advocacy groups. These groups highlight the lifesaving impact of such treatments for veterans seeking them abroad and aim to make them more accessible and potentially free within the United States.
Historical trials have demonstrated the effectiveness of these therapies. Research by the Multidisciplinary Association for Psychedelic Studies (MAPS) indicated that 88% of participants with severe PTSD experienced a significant reduction in symptoms, with 67% no longer meeting PTSD criteria after treatment. This groundbreaking initiative follows the fiscal 2024 budget’s amendment that specifically earmarks funds for psychedelic research, signaling a substantial shift in the federal government’s approach to veteran mental health care.
The endorsement of these trials by Congress, through the introduction of a provision by the Psychedelic Advancing Therapies Caucus, underscores a growing recognition of psychedelics’ medicinal properties. This move aligns with broader federal efforts, including the Defense Department’s provision passed in December to fund studies on psychedelic therapies for service members with PTSD or traumatic brain injuries.
Furthermore, the FDA’s recent decision to fast-track the review process for MDMA-assisted therapy, reducing it from the standard ten months to six, highlights the urgent need for effective PTSD treatments. With MDMA designated as a “breakthrough therapy” in 2017 and psilocybin receiving the same designation in 2019 for anxiety and depression treatments, there is a strong federal and scientific backing for these studies.
Expanded Coverage:
